Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1518567

Burden of esophageal cancer in global, regional and national regions from 1990 to 2021 and its projection until 2050: results from the GBD study 2021

Provisionally accepted
Chengcheng Zhang Chengcheng Zhang 1Linzhi Chen Linzhi Chen 1*Yuqi Xiu Yuqi Xiu 1*Hongling Zhang Hongling Zhang 1*Yuejuan Zhang Yuejuan Zhang 2*Wenjuan Ying Wenjuan Ying 1*
  • 1 First Affiliated Hospital of Shantou University Medical College, Shantou, China
  • 2 The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China

The final, formatted version of the article will be published soon.

    Abstract Background: Esophageal cancer (EC) is a major global health issue characterized by high morbidity and mortality rates, with a notably low five-year survival rate. Comprehensive analyses of the global burden of EC remain limited and outdated, despite its global significance. This study aimed to systematically assess the global burden and trends of esophageal cancer across diverse populations. Methods: Data on the burden of EC were collected from the Global Burden of Disease (GBD) 2021 study, including estimates of incidence, mortality, and disability-adjusted life years (DALYs), as well as risk factors, spanning 204 countries and territories. Age-standardized rates (ASRs) were calculated to allow comparisons across populations. The study further explored the relationship between EC burden and socioeconomic development by utilizing the Socio-demographic Index (SDI), aggregating data by regions. The Bayesian age-period-cohort model was applied to project future trends until 2050. Results: In 2021, there were 576,529 new esophageal cancer cases, with an age-standardized incidence rate (ASIR) of 6.65 per 100,000, reflecting a 24.87% decrease since 1990. The global number of deaths reached 538,602, with an age-standardized death rate (ASDR) of 6.25 per 100,000, representing a 30.67% decline. DALYs totaled 12,999,264, corresponding to an estimated annual percentage change (EAPC) of a 1.73% decrease in the age-standardized DALYs rate. East Asia accounted for nearly two-thirds of global EC cases and deaths, while Central Sub-Saharan Africa recorded the highest ASIR and ASDR. Central Asia experienced the largest reductions, whereas Western Sub-Saharan Africa showed increasing trends. Middle-SDI countries, such as Malawi and Lesotho, had disproportionately high burdens, while high-SDI countries, including Tunisia and Kuwait, had lower burdens. Males had higher incidence and mortality rates across all age groups. By 2050, the ASIR is projected to decrease to 6.17 per 100,000, and the ASDR to 5.23 per 100,000, though the absolute number of cases and deaths is expected to rise. Conclusions: The global burden of EC remains significant, with ongoing challenges in regions such as Africa and East Asia. These findings highlight the need for sustained and targeted prevention efforts, particularly in high-risk populations, to address the increasing absolute number of cases and deaths.

    Keywords: esophageal cancer1, Epidemiology2, incidence3, Mortality4, trend in global burden, Risk factor5, projection

    Received: 28 Oct 2024; Accepted: 27 Dec 2024.

    Copyright: © 2024 Zhang, Chen, Xiu, Zhang, Zhang and Ying. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Linzhi Chen, First Affiliated Hospital of Shantou University Medical College, Shantou, China
    Yuqi Xiu, First Affiliated Hospital of Shantou University Medical College, Shantou, China
    Hongling Zhang, First Affiliated Hospital of Shantou University Medical College, Shantou, China
    Yuejuan Zhang, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China
    Wenjuan Ying, First Affiliated Hospital of Shantou University Medical College, Shantou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.